BAJAJ BROKING

Notification
No new Notification messages
PDP Shipping & Projects IPO is Open!
Apply for the PDP Shipping & Projects IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

Sun Pharma to Acquire Checkpoint Therapeutics for $355 Million

Listen to our Podcast: Grow your wealth and keep it secure.

0:00 / 0:00

Synopsis:

Sun Pharma is set to acquire Checkpoint Therapeutics for up to $355 million. The deal includes an upfront payment of $4.10 per share, a 66% premium to Checkpoint’s last closing price. The acquisition strengthens Sun Pharma’s oncology segment, adding FDA-approved Unloxcyt to its portfolio.

 

Mumbai-based Sun Pharmaceutical Industries has finalised an agreement to acquire Checkpoint Therapeutics Inc. for up to $355 million (₹3,088 crore). This marks Sun Pharma’s second significant acquisition in two years, following its $576 million takeover of Concert Pharmaceuticals in 2023. The transaction is expected to close in the second quarter of 2025, pending regulatory approvals.

Also read: Bharat Electronics Secures ₹843 Crore in New Defence Orders

Key takeaways

  • Deal value: Sun Pharma will pay up to $355 million for Checkpoint Therapeutics.

  • Upfront payment: Shareholders will receive $4.10 per share, a 66% premium to Checkpoint’s closing price on 7 March 2025.

  • Contingent value rights: Additional payments of up to $0.70 per share depend on European regulatory approvals.

  • Strategic expansion: Sun Pharma strengthens its oncology portfolio, integrating Checkpoint’s FDA-approved Unloxcyt (cosibelimab-ipdl).

  • Financial performance: Checkpoint reported a $27.3 million net loss for the nine-month period ending September 2024.

Also read: Aditya Birla Capital Infuses ₹300 Crore into Housing Finance Subsidiary via Rights Issue

Sun Pharma’s offer and Checkpoint’s financials

Sun Pharma will acquire all outstanding shares of Checkpoint Therapeutics. Shareholders will receive $4.10 per share in cash, and an additional $0.70 per share if cosibelimab secures approval in key European markets.

Checkpoint Therapeutics, a Nasdaq-listed firm, is a commercial-stage immunotherapy company. Its lead product, Unloxcyt, is FDA-approved for cutaneous squamous cell carcinoma (cSCC). Despite this approval, Checkpoint faced financial struggles, with $0.04 million revenue and a $27.3 million net loss in the nine-month period ending September 2024.

Financial overview of Checkpoint Therapeutics

Metric

Value (as of September 2024)

Revenue

$0.04 million

Net loss

$27.3 million

Research and development expense

$19.3 million

Cash balance

$4.7 million

Accounts payable and accrued expenses

$15.6 million

Checkpoint’s controlling stockholder, Fortress Biotech, has agreed to vote in favour of the acquisition. Fortress will also receive royalty payments from cosibelimab’s future sales.

Strategic expansion in oncology

The acquisition bolsters Sun Pharma’s presence in the oncology segment, reinforcing its strategy of expanding innovative treatments. Unloxcyt’s integration into Sun Pharma’s global portfolio is expected to strengthen its market positioning in the US, Europe, and other key regions.

Checkpoint’s board of directors formed a special committee to evaluate strategic options. After assessing multiple offers, the committee approved Sun Pharma’s proposal as the best risk-adjusted value for stockholders.

With this acquisition, Sun Pharma continues its global expansion in oncology-focused treatments. By adding Checkpoint’s FDA-approved Unloxcyt, Sun Pharma is expected to enhance its oncology business and further increase Sun Pharma share price. The acquisition, if successful, will contribute to Sun Pharma’s revenue while strengthening its oncology research capabilities. Investors will now monitor Sun Pharma share price closely as the deal progresses through regulatory approvals.

Also read: Syngene International to Invest $56 Million in US Subsidiary Expansion

Do you have a trading account app or demat account app?

You can open an account with Bajaj Broking in minutes.

Download the Bajaj Broking app now from Play Store or App Store.

Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.

This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

For All Disclaimers Click Here: https://www.bajajbroking.in/disclaimer

Share this article: 

Frequently Asked Questions

No result found

search icon

Read More Blogs

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

9 lakh+ Users

icon-with-text

4.3+ App Rating

icon-with-text

4 Languages

icon-with-text

₹4300+ Cr MTF Book

icon-with-text